1. WLDS received a $750,000 grant from the Israel Innovation Authority. 2. The funding will support a clinical pilot program for Mudra Link technology. 3. Mudra Link aims to rehabilitate grip-force control in brain injury patients. 4. Pilot findings could position Mudra as a leading treatment standard. 5. The technology offers cost-effective therapy options with minimal supervision.
FAQ
Why Bullish?
The grant and clinical pilot program validate WLDS's innovative technology, potentially boosting market confidence similarly seen in previous biotech firms receiving funding, which often leads to stock price increases.
How important is it?
The approval of the grant and its intended use in a clinical pilot significantly affect WLDS's future as a player in medical tech, reinforcing investor and market optimism.
Why Long Term?
The clinical validation process may take time, but successful outcomes could establish WLDS as a leader in rehabilitation tech, reminiscent of other medical device firms that had to navigate lengthy approval processes.
Related Companies
Wearable Devices Secures $750,000 Grant for Neurorehabilitation Pilot with Soroka Medical Center
YOKNEAM ILLIT, ISRAEL, December 11, 2025 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW), a pioneering technology company specializing in AI-powered touchless sensing wearables, has announced the approval of a $750,000 grant from the Israel Innovation Authority (IIA). This grant will fund a clinical pilot program in collaboration with Soroka University Medical Center aimed at validating the company's Mudra Link neural wristband as a rehabilitation tool for patients experiencing impaired grip-force control following motor-cortex brain injuries.
Overview of the Mudra Link Clinical Pilot
The clinical pilot program will utilize patented surface neural ElectroMyography (EMG) technology, providing real-time, objective biofeedback to help patients train and correct their grip force. This initiative underscores the broader applicability of Mudra technology, which has demonstrated its effectiveness in neural interactions.
Expert Insights on Rehabilitation Technology
Guy Wagner, President and Chief Scientific Officer of Wearable Devices, stated, “Rehabilitation and assistive technologies have always been at the forefront of Brain-Computer Interface companies where there is a natural willingness to adopt transformative solutions.” He emphasized that the Mudra platform is designed to offer cost-effective therapy that can be performed at home with minimal therapist intervention, positioning it to potentially become the standard of care in grip-force neurorehabilitation worldwide.
Scientific Validation Led by Dr. Salman Zubedat
Dr. Salman Zubedat, leading the clinical pilot for Wearable Devices, noted that the current rehabilitation methods often lack the necessary consistency and quantitative performance tracking. He remarked, “Our pilot with Soroka Hospital represents a crucial scientific step toward clinical validation.” By leveraging the non-invasive capabilities of the Mudra Link, the initiative aims to set standardized performance metrics that could enhance treatment accessibility and expedite recovery for patients facing complex neurological motor deficits.
About Wearable Devices Ltd.
Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) leads in human-computer interaction through its innovation in AI-powered neural input touchless technology. The company offers advanced consumer products, such as the Mudra Band and Mudra Link, which facilitate intuitive and touch-free control of digital devices across multiple operating systems.
Through a dual-channel model combining direct-to-consumer sales and enterprise collaborations, Wearable Devices aims to enhance user experiences in gaming, productivity, and augmented reality (XR). The company's focus on setting the standard for neural input technology positions it well in rapidly growing tech markets.